H Mitsumoto

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
    H Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Neurology 68:1402-10. 2007
  2. ncbi request reprint Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    H Mitsumoto
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Suppl Clin Neurophysiol 59:327-32. 2006
  3. pmc Prevalence of depressive disorders and change over time in late-stage ALS
    J G Rabkin
    New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
    Neurology 65:62-7. 2005
  4. doi request reprint Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 72:1948-52. 2009
  5. pmc Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, California, USA
    Neurology 73:1227-33. 2009
  6. ncbi request reprint Incidence and predictors of PEG placement in ALS/MND
    S M Albert
    Eleanor and Lou Gehrig MDA ALS Center, Neurological Institute, Columbia University, New York, NY, USA
    J Neurol Sci 191:115-9. 2001
  7. doi request reprint Web-based data management for a phase II clinical trial in ALS
    Richard Buchsbaum
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:374-7. 2009
  8. pmc Study of 962 patients indicates progressive muscular atrophy is a form of ALS
    W K Kim
    The Eleanor and Lou Gehrig MDA ALS Research Center, The Neurological Institute of New York, Columbia University Medical Center, New York, NY 10032, USA
    Neurology 73:1686-92. 2009
  9. ncbi request reprint The ALSFRSr predicts survival time in an ALS clinic population
    P Kaufmann
    Department of Neurology, College of Physicians and Surgeons, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032, USA
    Neurology 64:38-43. 2005
  10. ncbi request reprint A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
    G Levy
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Neurology 66:660-3. 2006

Detail Information

Publications47

  1. ncbi request reprint Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
    H Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Neurology 68:1402-10. 2007
    ..To investigate the value of objective biomarkers for upper (UMN) and lower (LMN) motor neuron involvement in ALS...
  2. ncbi request reprint Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    H Mitsumoto
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Suppl Clin Neurophysiol 59:327-32. 2006
  3. pmc Prevalence of depressive disorders and change over time in late-stage ALS
    J G Rabkin
    New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
    Neurology 65:62-7. 2005
    ....
  4. doi request reprint Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 72:1948-52. 2009
    ..To determine how clinical features at the first evaluation and in follow-up can be used to suggest a diagnostic outcome for patients with only upper motor neuron (UMN) signs at disease onset...
  5. pmc Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, California, USA
    Neurology 73:1227-33. 2009
    ..To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS)...
  6. ncbi request reprint Incidence and predictors of PEG placement in ALS/MND
    S M Albert
    Eleanor and Lou Gehrig MDA ALS Center, Neurological Institute, Columbia University, New York, NY, USA
    J Neurol Sci 191:115-9. 2001
    ..3% of those "absolutely against" (p<0.01). PEG users were more likely to have initiated health care proxies. These findings suggest that patients who use PEG may be consistently proactive in the face of the disease...
  7. doi request reprint Web-based data management for a phase II clinical trial in ALS
    Richard Buchsbaum
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:374-7. 2009
    ..Given sufficient resources, a comprehensive web-based data management system can meet the need for clean, available data in clinical trials in ALS and similar diseases, and can contribute significantly to their efficient execution...
  8. pmc Study of 962 patients indicates progressive muscular atrophy is a form of ALS
    W K Kim
    The Eleanor and Lou Gehrig MDA ALS Research Center, The Neurological Institute of New York, Columbia University Medical Center, New York, NY 10032, USA
    Neurology 73:1686-92. 2009
    ..Whether PMA is actually a form of ALS has important consequences clinically and for therapeutic trials. We compared the survival of patients with PMA or ALS to analyze the clinical features that influence survival in PMA...
  9. ncbi request reprint The ALSFRSr predicts survival time in an ALS clinic population
    P Kaufmann
    Department of Neurology, College of Physicians and Surgeons, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032, USA
    Neurology 64:38-43. 2005
    ..To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in an ALS clinic population...
  10. ncbi request reprint A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
    G Levy
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Neurology 66:660-3. 2006
    ..The combination of a small pool of patients at any given time with the availability of many potential neuroprotective agents to be tested in ALS requires efficient phase II trial designs...
  11. ncbi request reprint Development and evaluation of a self-administered version of the ALSFRS-R
    J Montes
    Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032
    Neurology 67:1294-6. 2006
    ..The self-administered ALSFRS-R showed excellent reliability (intraclass correlation = 0.93, 95% CI: 088 to 0.96) and similar sensitivity to change over time vs the standard evaluator-administered ALSFRS-R...
  12. ncbi request reprint Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    P Kaufmann
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurologic Institute, Department of Neurology, Columbia University, New York 10032, USA
    Neurology 62:1753-7. 2004
    ..To develop objective markers for upper motor neuron (UMN) involvement in ALS, the value of single-voxel MR spectroscopy (MRS) and transcranial magnetic stimulation (TMS) was studied...
  13. doi request reprint Prevalence of fatigue and depression in ALS patients and change over time
    M C McElhiney
    New York State Psychiatric Institute, Unit 51, New York, NY 10032, USA
    J Neurol Neurosurg Psychiatry 80:1146-9. 2009
    ..Amyotrophic lateral sclerosis (ALS) patients report both fatigue and depression. It is not clear how frequently each occurs, to what extent they occur together, how each relates to ALS disease status, or their stability over time...
  14. ncbi request reprint The natural history of primary lateral sclerosis
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 66:647-53. 2006
    ....
  15. pmc Transcranial magnetic stimulation in ALS: utility of central motor conduction tests
    A G Floyd
    Clinical Motor Physiology Laboratory, Department of Neurology, Columbia University Medical Center, New York, NY, USA
    Neurology 72:498-504. 2009
    ..To investigate transcranial magnetic stimulation (TMS) measures as clinical correlates and longitudinal markers of amyotrophic lateral sclerosis (ALS)...
  16. pmc Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, California, USA
    Neurology 73:1218-26. 2009
    ..To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS)...
  17. ncbi request reprint Randomized controlled phase II trial of glatiramer acetate in ALS
    P H Gordon
    Department of Neurology, Columbia University, NY, USA
    Neurology 66:1117-9. 2006
    ..01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy...
  18. ncbi request reprint High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial
    D J Lange
    Department of Neurology, Mt Sinai School of Medicine, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    Neurology 67:991-7. 2006
    ..To evaluate changes in respiratory function in patients with ALS after using high-frequency chest wall oscillation (HFCWO)...
  19. ncbi request reprint Effects of cardiotrophin-1 (CT-1) in a mouse motor neuron disease
    H Mitsumoto
    Department of Neurology and Neurosciences, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Muscle Nerve 24:769-77. 2001
    ..01). We conclude that CT-1 exerts myotrophic effects as well as neurotrophic effects in a mouse model of spontaneous MND, a finding that has potential therapeutic implications for human MND...
  20. ncbi request reprint Genetic transfer of the wobbler gene to a C57BL/6J x NZB hybrid stock: natural history of the motor neuron disease and response to CNTF and BDNF cotreatment
    T Ishiyama
    Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
    Exp Neurol 148:247-55. 1997
    ..Thus, the hybrid B6NZB-wr/wr mice have a more severe clinical phenotype and offer a unique opportunity to study the mechanisms of presymptomatic motor neuron degeneration and the effects of therapeutic agents for human MND...
  21. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  22. pmc Wish to die in end-stage ALS
    S M Albert
    The Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University, New York, NY 10032, USA
    Neurology 65:68-74. 2005
    ..In retrospective studies, estimates of hastened dying among seriously ill patients range from <2% in one national survey to as much as 20% in end-stage disease cohorts...
  23. pmc Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
    Petra Kaufmann
    Department of Neurology, Clinical Coordinating Center, Columbia University, New York, NY 10032, USA
    Ann Neurol 66:235-44. 2009
    ..Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial...
  24. ncbi request reprint Identification of a novel mutation in Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis
    A Naini
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Neurol Sci 198:17-9. 2002
    ..The enzymatic activity of mutated SOD-1 measured in erythrocyte lysate was 70% of control. This heterozygote mutation, which is associated with the late onset of the disease, is located in the active site of the enzyme...
  25. ncbi request reprint Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry
    E P Pioro
    Department of Neurology, The Cleveland Clinic Foundation, OH 44195, USA
    Neuroreport 9:3041-6. 1998
    ..In vivo IH-MRS and correlative postmortem study of wobbler mouse brain will allow temporal monitoring of neuronal degeneration and responsiveness to neuroprotective pharmacotherapies...
  26. ncbi request reprint Patient-ventilator asynchrony with nocturnal noninvasive ventilation in ALS
    A D Atkeson
    Department of Medicine, the Cardiopulmonary Sleep and Ventilatory Disorders Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Neurology 77:549-55. 2011
    ..Despite the limited ability of NIV systems to deliver adequate ventilation synchronous with patient demand, nocturnal patient-ventilator asynchrony has not been systematically studied in patients with ALS prescribed such NIV...
  27. ncbi request reprint Development, analysis, refinement, and utility of an interdisciplinary amyotrophic lateral sclerosis database
    V Dal Bello-Haas
    Department of Neurology, The Cleveland Clinic Foundation, OH 44195, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:39-46. 2001
    ..Ongoing refinement will ensure that this HCP-driven ALS database continues to be informative, practical and effective for decision-making and enhancing delivery of care...
  28. ncbi request reprint A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS
    S N Scelsa
    Beth Israel Medical Center, New York, NY, USA
    Neurology 64:1298-300. 2005
    ..36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS...
  29. ncbi request reprint A clinical trial of creatine in ALS
    J M Shefner
    Department of Neurology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13104, USA
    Neurology 63:1656-61. 2004
    ..Creatine stabilizes the mitochondrial transition pore, and is important in mitochondrial ATP production. In a transgenic mouse model of ALS, administration of creatine prolongs survival and preserves motor function and motor neurons...
  30. ncbi request reprint Two novel SOD1 mutations in patients with familial amyotrophic lateral sclerosis
    H X Deng
    Department of Neurology, Northwestern University Medical School, Chicago, IL 60611, USA
    Hum Mol Genet 4:1113-6. 1995
  31. ncbi request reprint Exon 5 encoded domain is not required for the toxic function of mutant SOD1 but essential for the dismutase activity: identification and characterization of two new SOD1 mutations associated with familial amyotrophic lateral sclerosis
    J S Zu
    Department of Neurology, Northwestern Medical School, Chicago, IL 60611 3008, USA
    Neurogenetics 1:65-71. 1997
    ..These structural changes are proposed to cause a decrease in substrate specificity and an increase in the catalysis of harmful chemical reactions such as peroxidation...
  32. ncbi request reprint Novel mutations in spastin gene and absence of correlation with age at onset of symptoms
    A Hentati
    Department of Neurology, Northwestern Institute of Neurosciences, Northwestern University Medical School, Chicago, IL 60611, USA
    Neurology 55:1388-90. 2000
    ..We identified five novel mutations in the spastin gene in five families with SPG4 mutations from North America and Tunisia and showed the absence of correlation between the predicted mutant spastin protein and age at onset of symptoms...
  33. ncbi request reprint Clinical trials: present and future
    H Mitsumoto
    Eleanor and Lou Gehrig MDA/ALS Center, Columbia-Presbyterian Medical Center, New York, NY, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:S10-4. 2001
    ..Effort must also be directed towards the search for objective markers for ALS...
  34. ncbi request reprint Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction
    H Mitsumoto
    Elenor and Lou Gehrig MDA ALS Research Center, The Neurologic Institute, Columbia University, New York 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:177-85. 2003
    ..To compare characteristics of ALS patients with and without percutaneous endoscopic gastrostomy (PEG)...
  35. ncbi request reprint Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
    K Ikeda
    Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 37:505-11. 1995
    ..0001). This study establishes that exogenous BDNF administration can retard motor dysfunction in a natural MND and diminish denervation muscle atrophy and motor axon loss...
  36. ncbi request reprint Phase II/III randomized trial of TCH346 in patients with ALS
    R Miller
    California Pacific Medical Center, San Francisco, CA 94115, USA
    Neurology 69:776-84. 2007
    ..Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS...
  37. ncbi request reprint Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF
    H Mitsumoto
    Department of Neurology, Cleveland Clinic Foundation, OH 44195
    Science 265:1107-10. 1994
    ..Subcutaneous injection of the two factors on alternate days was found to arrest disease progression in wobbler mice for 1 month, as measured by several behavioral, physiological, and histological criteria...
  38. ncbi request reprint Occurrence of amyotrophic lateral sclerosis among Gulf War veterans
    R D Horner
    National Institute of Neurological Disorders and Stroke, Bethesda, MD 20852, USA
    Neurology 61:742-9. 2003
    ..In response to Gulf War veterans' concerns of high rates of ALS, this investigation sought to determine if Gulf War veterans have an elevated rate of ALS...
  39. ncbi request reprint A randomized controlled trial of resistance exercise in individuals with ALS
    V Dal Bello-Haas
    School of Physical Therapy, University of Saskatchewan, Saskatoon, SK, Canada
    Neurology 68:2003-7. 2007
    ..To determine the effects of resistance exercise on function, fatigue, and quality of life in individuals with ALS...
  40. ncbi request reprint In vivo and in vitro muscle tensions in wobbler mouse motor neuron disease
    K Ikeda
    Muscle Nerve 16:979-81. 1993
  41. ncbi request reprint Impaired slow axonal transport in wobbler mouse motor neuron disease
    H Mitsumoto
    Ann Neurol 19:36-43. 1986
    ..abstract truncated at 250 words)..
  42. ncbi request reprint Role of brain-derived neurotrophic factor in wobbler mouse motor neuron disease
    K Tsuzaka
    Department of Neurology and Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Muscle Nerve 24:474-80. 2001
    ..Our study indicates that BDNF is important in halting nitric oxide (NO)-mediated motor neuron degeneration, which has potential implications for the treatment of neurodegenerative disorders...
  43. ncbi request reprint Excitatory amino acid receptor antagonist in murine motoneuron disease (the wobbler mouse)
    C Krieger
    Division of Neurology, University of British Columbia, Vancouver, Canada
    Can J Neurol Sci 19:462-5. 1992
    ..We conclude that NMDA receptor activation is probably not involved in the pathogenesis of motoneuron loss in the wobbler mouse...
  44. ncbi request reprint The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
    H Mitsumoto
    Department of Neurology, Cleveland Clinic Foundation, OH
    Ann Neurol 36:142-8. 1994
    ..005) and muscle twitch tension was greater (p < 0.002) in ciliary neurotrophic factor-treated animals. Thus, ciliary neurotrophic factor retarded the disease progression and improved muscle strength in this motor neuron disease model...
  45. ncbi request reprint Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease
    K Ikeda
    Department of Neurology, Cleveland Clinic Foundation, OH 44195
    Ann Neurol 37:47-54. 1995
    ..The number of terminal axonal branching points and the mean length of motor end-plates were also higher in the ciliary neurotrophic factor-treated mice (p < 0.001 and p < 0.02, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)..
  46. ncbi request reprint Retardation of fast axonal transport in wobbler mice
    H Mitsumoto
    Department of Neurology, Cleveland Clinic Foundation, OH 44195
    Muscle Nerve 16:542-7. 1993
    ..Muscle & Nerve 13:121-126, 1990), we conclude that wobbler disease specifically retards anterograde FC in less-affected hindlimb motor neurons, whereas all components of axonal transport are retarded in forelimb motor neurons...
  47. ncbi request reprint MMT vs MVIC: low-tech scores high?
    P N Leigh
    Neurology 61:1472-3. 2003